#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=The Effects of Music Intervention on Functional Connectivity Strength of the Brain in Schizophrenia Schizophrenia is often associated with behavior abnormality in the cognitive and affective domain.
1-1	0-3	The	_
1-2	4-11	Effects	_
1-3	12-14	of	_
1-4	15-20	Music	_
1-5	21-33	Intervention	_
1-6	34-36	on	_
1-7	37-47	Functional	_
1-8	48-60	Connectivity	_
1-9	61-69	Strength	_
1-10	70-72	of	_
1-11	73-76	the	_
1-12	77-82	Brain	_
1-13	83-85	in	_
1-14	86-99	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-15	100-113	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	114-116	is	_
1-17	117-122	often	_
1-18	123-133	associated	_
1-19	134-138	with	_
1-20	139-147	behavior	_
1-21	148-159	abnormality	_
1-22	160-162	in	_
1-23	163-166	the	_
1-24	167-176	cognitive	_
1-25	177-180	and	_
1-26	181-190	affective	_
1-27	191-197	domain	_
1-28	198-199	.	_

Text=Music intervention is used as a complementary treatment for improving symptoms in patients with schizophrenia.
2-1	200-205	Music	_
2-2	206-218	intervention	_
2-3	219-221	is	_
2-4	222-226	used	_
2-5	227-229	as	_
2-6	230-231	a	_
2-7	232-245	complementary	_
2-8	246-255	treatment	_
2-9	256-259	for	_
2-10	260-269	improving	_
2-11	270-278	symptoms	_
2-12	279-281	in	_
2-13	282-290	patients	_
2-14	291-295	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-15	296-309	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-16	310-311	.	_

Text=However, the neurophysiological correlates of these remissions remain poorly understood.
3-1	312-319	However	_
3-2	320-321	,	_
3-3	322-325	the	_
3-4	326-344	neurophysiological	_
3-5	345-355	correlates	_
3-6	356-358	of	_
3-7	359-364	these	_
3-8	365-375	remissions	_
3-9	376-382	remain	_
3-10	383-389	poorly	_
3-11	390-400	understood	_
3-12	401-402	.	_

Text=Here, we investigated the effects of music intervention in neural circuits through functional magnetic resonance imaging (fMRI) study in schizophrenic subjects.
4-1	403-407	Here	_
4-2	408-409	,	_
4-3	410-412	we	_
4-4	413-425	investigated	_
4-5	426-429	the	_
4-6	430-437	effects	_
4-7	438-440	of	_
4-8	441-446	music	_
4-9	447-459	intervention	_
4-10	460-462	in	_
4-11	463-469	neural	_
4-12	470-478	circuits	_
4-13	479-486	through	_
4-14	487-497	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-15	498-506	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-16	507-516	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-17	517-524	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-18	525-526	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-19	527-531	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-20	532-533	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-21	534-539	study	_
4-22	540-542	in	_
4-23	543-556	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-24	557-565	subjects	_
4-25	566-567	.	_

Text=Under the standard care, patients were randomly assigned to music and non-music interventions (MTSZ, UMTSZ) for 1 month.
5-1	568-573	Under	_
5-2	574-577	the	_
5-3	578-586	standard	_
5-4	587-591	care	_
5-5	592-593	,	_
5-6	594-602	patients	_
5-7	603-607	were	_
5-8	608-616	randomly	_
5-9	617-625	assigned	_
5-10	626-628	to	_
5-11	629-634	music	_
5-12	635-638	and	_
5-13	639-648	non-music	_
5-14	649-662	interventions	_
5-15	663-664	(	_
5-16	665-669	MTSZ	_
5-17	670-671	,	_
5-18	672-677	UMTSZ	_
5-19	678-679	)	_
5-20	680-683	for	_
5-21	684-685	1	_
5-22	686-691	month	_
5-23	692-693	.	_

Text=Resting-state fMRI were acquired over three time points (baseline, 1 month, and 6 months later) in patients and analyzed using functional connectivity strength (FCS) and seed-based functional connection (FC) approaches.
6-1	694-707	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
6-2	708-712	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
6-3	713-717	were	_
6-4	718-726	acquired	_
6-5	727-731	over	_
6-6	732-737	three	_
6-7	738-742	time	_
6-8	743-749	points	_
6-9	750-751	(	_
6-10	752-760	baseline	_
6-11	761-762	,	_
6-12	763-764	1	_
6-13	765-770	month	_
6-14	771-772	,	_
6-15	773-776	and	_
6-16	777-778	6	_
6-17	779-785	months	_
6-18	786-791	later	_
6-19	792-793	)	_
6-20	794-796	in	_
6-21	797-805	patients	_
6-22	806-809	and	_
6-23	810-818	analyzed	_
6-24	819-824	using	_
6-25	825-835	functional	_
6-26	836-848	connectivity	_
6-27	849-857	strength	_
6-28	858-859	(	_
6-29	860-863	FCS	_
6-30	864-865	)	_
6-31	866-869	and	_
6-32	870-880	seed-based	_
6-33	881-891	functional	_
6-34	892-902	connection	_
6-35	903-904	(	_
6-36	905-907	FC	_
6-37	908-909	)	_
6-38	910-920	approaches	_
6-39	921-922	.	_

Text=At baseline, compared with healthy controls, decreased FCS in the right middle temporal gyrus (MTG) was observed in patients.
7-1	923-925	At	_
7-2	926-934	baseline	_
7-3	935-936	,	_
7-4	937-945	compared	_
7-5	946-950	with	_
7-6	951-958	healthy	_
7-7	959-967	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-8	968-969	,	_
7-9	970-979	decreased	_
7-10	980-983	FCS	_
7-11	984-986	in	_
7-12	987-990	the	_
7-13	991-996	right	_
7-14	997-1003	middle	_
7-15	1004-1012	temporal	_
7-16	1013-1018	gyrus	_
7-17	1019-1020	(	_
7-18	1021-1024	MTG	_
7-19	1025-1026	)	_
7-20	1027-1030	was	_
7-21	1031-1039	observed	_
7-22	1040-1042	in	_
7-23	1043-1051	patients	_
7-24	1052-1053	.	_

Text=However, after music intervention, the functional circuitry of the right MTG, which was related with the function of emotion and sensorimotor, was improved in MTSZ.
8-1	1054-1061	However	_
8-2	1062-1063	,	_
8-3	1064-1069	after	_
8-4	1070-1075	music	_
8-5	1076-1088	intervention	_
8-6	1089-1090	,	_
8-7	1091-1094	the	_
8-8	1095-1105	functional	_
8-9	1106-1115	circuitry	_
8-10	1116-1118	of	_
8-11	1119-1122	the	_
8-12	1123-1128	right	_
8-13	1129-1132	MTG	_
8-14	1133-1134	,	_
8-15	1135-1140	which	_
8-16	1141-1144	was	_
8-17	1145-1152	related	_
8-18	1153-1157	with	_
8-19	1158-1161	the	_
8-20	1162-1170	function	_
8-21	1171-1173	of	_
8-22	1174-1181	emotion	_
8-23	1182-1185	and	_
8-24	1186-1198	sensorimotor	_
8-25	1199-1200	,	_
8-26	1201-1204	was	_
8-27	1205-1213	improved	_
8-28	1214-1216	in	_
8-29	1217-1221	MTSZ	_
8-30	1222-1223	.	_

Text=Furthermore, the FC increments were significantly correlated with the improvement of symptoms, while vanishing 6 months later.
9-1	1224-1235	Furthermore	_
9-2	1236-1237	,	_
9-3	1238-1241	the	_
9-4	1242-1244	FC	_
9-5	1245-1255	increments	_
9-6	1256-1260	were	_
9-7	1261-1274	significantly	_
9-8	1275-1285	correlated	_
9-9	1286-1290	with	_
9-10	1291-1294	the	_
9-11	1295-1306	improvement	_
9-12	1307-1309	of	_
9-13	1310-1318	symptoms	_
9-14	1319-1320	,	_
9-15	1321-1326	while	_
9-16	1327-1336	vanishing	_
9-17	1337-1338	6	_
9-18	1339-1345	months	_
9-19	1346-1351	later	_
9-20	1352-1353	.	_

Text=Together, these findings provided evidence that music intervention might positively modulate the functional connectivity of MTG in patients with schizophrenia; such changes might be associated with the observed therapeutic effects of music intervention on neurocognitive function.
10-1	1354-1362	Together	_
10-2	1363-1364	,	_
10-3	1365-1370	these	_
10-4	1371-1379	findings	_
10-5	1380-1388	provided	_
10-6	1389-1397	evidence	_
10-7	1398-1402	that	_
10-8	1403-1408	music	_
10-9	1409-1421	intervention	_
10-10	1422-1427	might	_
10-11	1428-1438	positively	_
10-12	1439-1447	modulate	_
10-13	1448-1451	the	_
10-14	1452-1462	functional	_
10-15	1463-1475	connectivity	_
10-16	1476-1478	of	_
10-17	1479-1482	MTG	_
10-18	1483-1485	in	_
10-19	1486-1494	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-20	1495-1499	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-21	1500-1513	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-22	1514-1515	;	_
10-23	1516-1520	such	_
10-24	1521-1528	changes	_
10-25	1529-1534	might	_
10-26	1535-1537	be	_
10-27	1538-1548	associated	_
10-28	1549-1553	with	_
10-29	1554-1557	the	_
10-30	1558-1566	observed	_
10-31	1567-1578	therapeutic	_
10-32	1579-1586	effects	_
10-33	1587-1589	of	_
10-34	1590-1595	music	_
10-35	1596-1608	intervention	_
10-36	1609-1611	on	_
10-37	1612-1626	neurocognitive	_
10-38	1627-1635	function	_
10-39	1636-1637	.	_

Text=This trial is registered with ChiCTR-OPC-14005339.
11-1	1638-1642	This	_
11-2	1643-1648	trial	_
11-3	1649-1651	is	_
11-4	1652-1662	registered	_
11-5	1663-1667	with	_
11-6	1668-1687	ChiCTR-OPC-14005339	_
11-7	1688-1689	.	_

Text=2.
12-1	1690-1691	2	_
12-2	1692-1693	.	_

Text=Material and Methods 2.1.
13-1	1694-1702	Material	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	1703-1706	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	1707-1714	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	1715-1718	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-5	1719-1720	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

Text=Subjects The participants in this study are the same with our previous study including fifty-six schizophrenic subjects (male: 10; female: 26) and nineteen healthy controls (HC) (male: 7; female: 12).
14-1	1721-1729	Subjects	_
14-2	1730-1733	The	_
14-3	1734-1746	participants	_
14-4	1747-1749	in	_
14-5	1750-1754	this	_
14-6	1755-1760	study	_
14-7	1761-1764	are	_
14-8	1765-1768	the	_
14-9	1769-1773	same	_
14-10	1774-1778	with	_
14-11	1779-1782	our	_
14-12	1783-1791	previous	_
14-13	1792-1797	study	_
14-14	1798-1807	including	_
14-15	1808-1817	fifty-six	_
14-16	1818-1831	schizophrenic	_
14-17	1832-1840	subjects	_
14-18	1841-1842	(	_
14-19	1843-1847	male	_
14-20	1848-1849	:	_
14-21	1850-1852	10	_
14-22	1853-1854	;	_
14-23	1855-1861	female	_
14-24	1862-1863	:	_
14-25	1864-1866	26	_
14-26	1867-1868	)	_
14-27	1869-1872	and	_
14-28	1873-1881	nineteen	_
14-29	1882-1889	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-30	1890-1898	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-31	1899-1900	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-32	1901-1903	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-33	1904-1905	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-34	1906-1907	(	_
14-35	1908-1912	male	_
14-36	1913-1914	:	_
14-37	1915-1916	7	_
14-38	1917-1918	;	_
14-39	1919-1925	female	_
14-40	1926-1927	:	_
14-41	1928-1930	12	_
14-42	1931-1932	)	_
14-43	1933-1934	.	_

Text=All subjects were recruited from the clinical hospital of the Chengdu Brain Science Institute (CBSI).
15-1	1935-1938	All	_
15-2	1939-1947	subjects	_
15-3	1948-1952	were	_
15-4	1953-1962	recruited	_
15-5	1963-1967	from	_
15-6	1968-1971	the	_
15-7	1972-1980	clinical	_
15-8	1981-1989	hospital	_
15-9	1990-1992	of	_
15-10	1993-1996	the	_
15-11	1997-2004	Chengdu	_
15-12	2005-2010	Brain	_
15-13	2011-2018	Science	_
15-14	2019-2028	Institute	_
15-15	2029-2030	(	_
15-16	2031-2035	CBSI	_
15-17	2036-2037	)	_
15-18	2038-2039	.	_

Text=The detail fundamental information of schizophrenic subjects and HC could be referred to our previous article.
16-1	2040-2043	The	_
16-2	2044-2050	detail	_
16-3	2051-2062	fundamental	_
16-4	2063-2074	information	_
16-5	2075-2077	of	_
16-6	2078-2091	schizophrenic	_
16-7	2092-2100	subjects	_
16-8	2101-2104	and	_
16-9	2105-2107	HC	_
16-10	2108-2113	could	_
16-11	2114-2116	be	_
16-12	2117-2125	referred	_
16-13	2126-2128	to	_
16-14	2129-2132	our	_
16-15	2133-2141	previous	_
16-16	2142-2149	article	_
16-17	2150-2151	.	_

Text=2.2.
17-1	2152-2155	2.2	_
17-2	2156-2157	.	_

Text=Design To measure the effect of music intervention on schizophrenic subjects, a quasirandomized controlled trial was conducted in this study.
18-1	2158-2164	Design	_
18-2	2165-2167	To	_
18-3	2168-2175	measure	_
18-4	2176-2179	the	_
18-5	2180-2186	effect	_
18-6	2187-2189	of	_
18-7	2190-2195	music	_
18-8	2196-2208	intervention	_
18-9	2209-2211	on	_
18-10	2212-2225	schizophrenic	_
18-11	2226-2234	subjects	_
18-12	2235-2236	,	_
18-13	2237-2238	a	_
18-14	2239-2254	quasirandomized	_
18-15	2255-2265	controlled	_
18-16	2266-2271	trial	_
18-17	2272-2275	was	_
18-18	2276-2285	conducted	_
18-19	2286-2288	in	_
18-20	2289-2293	this	_
18-21	2294-2299	study	_
18-22	2300-2301	.	_

Text=Twenty-two patients with schizophrenia, who were randomly selected from patients, received group music intervention (MTSZ: music intervention patients with schizophrenia).
19-1	2302-2312	Twenty-two	_
19-2	2313-2321	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-3	2322-2326	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-4	2327-2340	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-5	2341-2342	,	_
19-6	2343-2346	who	_
19-7	2347-2351	were	_
19-8	2352-2360	randomly	_
19-9	2361-2369	selected	_
19-10	2370-2374	from	_
19-11	2375-2383	patients	_
19-12	2384-2385	,	_
19-13	2386-2394	received	_
19-14	2395-2400	group	_
19-15	2401-2406	music	_
19-16	2407-2419	intervention	_
19-17	2420-2421	(	_
19-18	2422-2426	MTSZ	_
19-19	2427-2428	:	_
19-20	2429-2434	music	_
19-21	2435-2447	intervention	_
19-22	2448-2456	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-23	2457-2461	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-24	2462-2475	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-25	2476-2477	)	_
19-26	2478-2479	.	_

Text=Controlled patients (UMTSZ: non-music intervention patients with schizophrenia, remaining twenty-three patients) received standard care only.
20-1	2480-2490	Controlled	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
20-2	2491-2499	patients	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
20-3	2500-2501	(	_
20-4	2502-2507	UMTSZ	_
20-5	2508-2509	:	_
20-6	2510-2519	non-music	_
20-7	2520-2532	intervention	_
20-8	2533-2541	patients	_
20-9	2542-2546	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-10	2547-2560	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-11	2561-2562	,	_
20-12	2563-2572	remaining	_
20-13	2573-2585	twenty-three	_
20-14	2586-2594	patients	_
20-15	2595-2596	)	_
20-16	2597-2605	received	_
20-17	2606-2614	standard	_
20-18	2615-2619	care	_
20-19	2620-2624	only	_
20-20	2625-2626	.	_

Text=Three time point tests were included: a baseline test, a 1-month follow-up, and a 6-month follow-up.
21-1	2627-2632	Three	_
21-2	2633-2637	time	_
21-3	2638-2643	point	_
21-4	2644-2649	tests	_
21-5	2650-2654	were	_
21-6	2655-2663	included	_
21-7	2664-2665	:	_
21-8	2666-2667	a	_
21-9	2668-2676	baseline	_
21-10	2677-2681	test	_
21-11	2682-2683	,	_
21-12	2684-2685	a	_
21-13	2686-2693	1-month	_
21-14	2694-2703	follow-up	_
21-15	2704-2705	,	_
21-16	2706-2709	and	_
21-17	2710-2711	a	_
21-18	2712-2719	6-month	_
21-19	2720-2729	follow-up	_
21-20	2730-2731	.	_

Text=The blinded assessments and assignment were performed in schizophrenic subjects.
22-1	2732-2735	The	_
22-2	2736-2743	blinded	_
22-3	2744-2755	assessments	_
22-4	2756-2759	and	_
22-5	2760-2770	assignment	_
22-6	2771-2775	were	_
22-7	2776-2785	performed	_
22-8	2786-2788	in	_
22-9	2789-2802	schizophrenic	_
22-10	2803-2811	subjects	_
22-11	2812-2813	.	_

Text=The design of music intervention in this study was the same with our previous work.
23-1	2814-2817	The	_
23-2	2818-2824	design	_
23-3	2825-2827	of	_
23-4	2828-2833	music	_
23-5	2834-2846	intervention	_
23-6	2847-2849	in	_
23-7	2850-2854	this	_
23-8	2855-2860	study	_
23-9	2861-2864	was	_
23-10	2865-2868	the	_
23-11	2869-2873	same	_
23-12	2874-2878	with	_
23-13	2879-2882	our	_
23-14	2883-2891	previous	_
23-15	2892-2896	work	_
23-16	2897-2898	.	_

Text=The detailed information could be referred from the previous article.
24-1	2899-2902	The	_
24-2	2903-2911	detailed	_
24-3	2912-2923	information	_
24-4	2924-2929	could	_
24-5	2930-2932	be	_
24-6	2933-2941	referred	_
24-7	2942-2946	from	_
24-8	2947-2950	the	_
24-9	2951-2959	previous	_
24-10	2960-2967	article	_
24-11	2968-2969	.	_

Text=2.3.
25-1	2970-2973	2.3	_
25-2	2974-2975	.	_

Text=Content of Music Intervention One professional music therapist participated in this study.
26-1	2976-2983	Content	_
26-2	2984-2986	of	_
26-3	2987-2992	Music	_
26-4	2993-3005	Intervention	_
26-5	3006-3009	One	_
26-6	3010-3022	professional	_
26-7	3023-3028	music	_
26-8	3029-3038	therapist	_
26-9	3039-3051	participated	_
26-10	3052-3054	in	_
26-11	3055-3059	this	_
26-12	3060-3065	study	_
26-13	3066-3067	.	_

Text=Mozart's sonata K.448 music listening was performed in the MTSZ group (30 minutes per day, 30 days).
27-1	3068-3074	Mozart	_
27-2	3075-3077	's	_
27-3	3078-3084	sonata	_
27-4	3085-3090	K.448	_
27-5	3091-3096	music	_
27-6	3097-3106	listening	_
27-7	3107-3110	was	_
27-8	3111-3120	performed	_
27-9	3121-3123	in	_
27-10	3124-3127	the	_
27-11	3128-3132	MTSZ	_
27-12	3133-3138	group	_
27-13	3139-3140	(	_
27-14	3141-3143	30	_
27-15	3144-3151	minutes	_
27-16	3152-3155	per	_
27-17	3156-3159	day	_
27-18	3160-3161	,	_
27-19	3162-3164	30	_
27-20	3165-3169	days	_
27-21	3170-3171	)	_
27-22	3172-3173	.	_

Text=MTSZ patients peacefully listened to the music in a quiet room during each session.
28-1	3174-3178	MTSZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
28-2	3179-3187	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
28-3	3188-3198	peacefully	_
28-4	3199-3207	listened	_
28-5	3208-3210	to	_
28-6	3211-3214	the	_
28-7	3215-3220	music	_
28-8	3221-3223	in	_
28-9	3224-3225	a	_
28-10	3226-3231	quiet	_
28-11	3232-3236	room	_
28-12	3237-3243	during	_
28-13	3244-3248	each	_
28-14	3249-3256	session	_
28-15	3257-3258	.	_

Text=The music therapist introduced the background of the music to schizophrenic patients at the beginning.
29-1	3259-3262	The	_
29-2	3263-3268	music	_
29-3	3269-3278	therapist	_
29-4	3279-3289	introduced	_
29-5	3290-3293	the	_
29-6	3294-3304	background	_
29-7	3305-3307	of	_
29-8	3308-3311	the	_
29-9	3312-3317	music	_
29-10	3318-3320	to	_
29-11	3321-3334	schizophrenic	_
29-12	3335-3343	patients	_
29-13	3344-3346	at	_
29-14	3347-3350	the	_
29-15	3351-3360	beginning	_
29-16	3361-3362	.	_

Text=The UMTSZ was treated solely with antipsychotic drugs.
30-1	3363-3366	The	_
30-2	3367-3372	UMTSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-3	3373-3376	was	_
30-4	3377-3384	treated	_
30-5	3385-3391	solely	_
30-6	3392-3396	with	_
30-7	3397-3410	antipsychotic	_
30-8	3411-3416	drugs	_
30-9	3417-3418	.	_

Text=The content of the music intervention was also the same with our previous study.
31-1	3419-3422	The	_
31-2	3423-3430	content	_
31-3	3431-3433	of	_
31-4	3434-3437	the	_
31-5	3438-3443	music	_
31-6	3444-3456	intervention	_
31-7	3457-3460	was	_
31-8	3461-3465	also	_
31-9	3466-3469	the	_
31-10	3470-3474	same	_
31-11	3475-3479	with	_
31-12	3480-3483	our	_
31-13	3484-3492	previous	_
31-14	3493-3498	study	_
31-15	3499-3500	.	_

Text=The detailed information could be referred from the previous article.
32-1	3501-3504	The	_
32-2	3505-3513	detailed	_
32-3	3514-3525	information	_
32-4	3526-3531	could	_
32-5	3532-3534	be	_
32-6	3535-3543	referred	_
32-7	3544-3548	from	_
32-8	3549-3552	the	_
32-9	3553-3561	previous	_
32-10	3562-3569	article	_
32-11	3570-3571	.	_

Text=2.4.
33-1	3572-3575	2.4	_
33-2	3576-3577	.	_

Text=Psychiatric and Neuropsychological Assessment Three evaluators of the neuropsychological assessments and one psychiatrist assessed the patients with schizophrenia.
34-1	3578-3589	Psychiatric	_
34-2	3590-3593	and	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
34-3	3594-3612	Neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
34-4	3613-3623	Assessment	_
34-5	3624-3629	Three	_
34-6	3630-3640	evaluators	_
34-7	3641-3643	of	_
34-8	3644-3647	the	_
34-9	3648-3666	neuropsychological	_
34-10	3667-3678	assessments	_
34-11	3679-3682	and	_
34-12	3683-3686	one	_
34-13	3687-3699	psychiatrist	_
34-14	3700-3708	assessed	_
34-15	3709-3712	the	_
34-16	3713-3721	patients	_
34-17	3722-3726	with	_
34-18	3727-3740	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
34-19	3741-3742	.	_

Text=The psychiatric symptoms of the schizophrenic patients were assessed by a psychiatrist using the Positive and Negative Symptom Scale (PANSS).
35-1	3743-3746	The	_
35-2	3747-3758	psychiatric	_
35-3	3759-3767	symptoms	_
35-4	3768-3770	of	_
35-5	3771-3774	the	_
35-6	3775-3788	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
35-7	3789-3797	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
35-8	3798-3802	were	_
35-9	3803-3811	assessed	_
35-10	3812-3814	by	_
35-11	3815-3816	a	_
35-12	3817-3829	psychiatrist	_
35-13	3830-3835	using	_
35-14	3836-3839	the	_
35-15	3840-3848	Positive	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
35-16	3849-3852	and	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
35-17	3853-3861	Negative	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
35-18	3862-3869	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
35-19	3870-3875	Scale	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
35-20	3876-3877	(	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
35-21	3878-3883	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
35-22	3884-3885	)	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
35-23	3886-3887	.	_

Text=In the neuropsychological assessment (Block Design Test (BDT), BVRT, and Spatial Maze Test), the evaluators were trained to achieve a high interrater reliability before the start of the study.
36-1	3888-3890	In	_
36-2	3891-3894	the	_
36-3	3895-3913	neuropsychological	_
36-4	3914-3924	assessment	_
36-5	3925-3926	(	_
36-6	3927-3932	Block	_
36-7	3933-3939	Design	_
36-8	3940-3944	Test	_
36-9	3945-3946	(	_
36-10	3947-3950	BDT	_
36-11	3951-3952	)	_
36-12	3953-3954	,	_
36-13	3955-3959	BVRT	_
36-14	3960-3961	,	_
36-15	3962-3965	and	_
36-16	3966-3973	Spatial	_
36-17	3974-3978	Maze	_
36-18	3979-3983	Test	_
36-19	3984-3985	)	_
36-20	3986-3987	,	_
36-21	3988-3991	the	_
36-22	3992-4002	evaluators	_
36-23	4003-4007	were	_
36-24	4008-4015	trained	_
36-25	4016-4018	to	_
36-26	4019-4026	achieve	_
36-27	4027-4028	a	_
36-28	4029-4033	high	_
36-29	4034-4044	interrater	_
36-30	4045-4056	reliability	_
36-31	4057-4063	before	_
36-32	4064-4067	the	_
36-33	4068-4073	start	_
36-34	4074-4076	of	_
36-35	4077-4080	the	_
36-36	4081-4086	study	_
36-37	4087-4088	.	_

Text=Detailed information can be found in Section 1 of the Supplemental Information).
37-1	4089-4097	Detailed	_
37-2	4098-4109	information	_
37-3	4110-4113	can	_
37-4	4114-4116	be	_
37-5	4117-4122	found	_
37-6	4123-4125	in	_
37-7	4126-4133	Section	_
37-8	4134-4135	1	_
37-9	4136-4138	of	_
37-10	4139-4142	the	_
37-11	4143-4155	Supplemental	_
37-12	4156-4167	Information	_
37-13	4168-4169	)	_
37-14	4170-4171	.	_

Text=2.5.
38-1	4172-4175	2.5	_
38-2	4176-4177	.	_

Text=Data Acquisition Experiments were performed on a 3 T MRI scanner (GE Discovery MR750).
39-1	4178-4182	Data	_
39-2	4183-4194	Acquisition	_
39-3	4195-4206	Experiments	_
39-4	4207-4211	were	_
39-5	4212-4221	performed	_
39-6	4222-4224	on	_
39-7	4225-4226	a	_
39-8	4227-4228	3	_
39-9	4229-4230	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-10	4231-4234	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-11	4235-4242	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-12	4243-4244	(	_
39-13	4245-4247	GE	_
39-14	4248-4257	Discovery	_
39-15	4258-4263	MR750	_
39-16	4264-4265	)	_
39-17	4266-4267	.	_

Text=A detailed description of the data collection can be found in Section 2 of the Supplemental Information.
40-1	4268-4269	A	_
40-2	4270-4278	detailed	_
40-3	4279-4290	description	_
40-4	4291-4293	of	_
40-5	4294-4297	the	_
40-6	4298-4302	data	_
40-7	4303-4313	collection	_
40-8	4314-4317	can	_
40-9	4318-4320	be	_
40-10	4321-4326	found	_
40-11	4327-4329	in	_
40-12	4330-4337	Section	_
40-13	4338-4339	2	_
40-14	4340-4342	of	_
40-15	4343-4346	the	_
40-16	4347-4359	Supplemental	_
40-17	4360-4371	Information	_
40-18	4372-4373	.	_

Text=Functional image preprocessing was performed using SPM8 (Statistical Parametric Mapping, http: //www.fil.ion.ucl.ac.uk/spm/) according to a standard pipeline.
41-1	4374-4384	Functional	_
41-2	4385-4390	image	_
41-3	4391-4404	preprocessing	_
41-4	4405-4408	was	_
41-5	4409-4418	performed	_
41-6	4419-4424	using	_
41-7	4425-4429	SPM8	_
41-8	4430-4431	(	_
41-9	4432-4443	Statistical	_
41-10	4444-4454	Parametric	_
41-11	4455-4462	Mapping	_
41-12	4463-4464	,	_
41-13	4465-4469	http	_
41-14	4470-4471	:	_
41-15	4472-4500	//www.fil.ion.ucl.ac.uk/spm/	_
41-16	4501-4502	)	_
41-17	4503-4512	according	_
41-18	4513-4515	to	_
41-19	4516-4517	a	_
41-20	4518-4526	standard	_
41-21	4527-4535	pipeline	_
41-22	4536-4537	.	_

Text=Slice timing correction and head motion correction were carried out.
42-1	4538-4543	Slice	_
42-2	4544-4550	timing	_
42-3	4551-4561	correction	_
42-4	4562-4565	and	_
42-5	4566-4570	head	_
42-6	4571-4577	motion	_
42-7	4578-4588	correction	_
42-8	4589-4593	were	_
42-9	4594-4601	carried	_
42-10	4602-4605	out	_
42-11	4606-4607	.	_

Text=Then, the functional scans were normalized to the Montreal Neurological Institute (MNI) EPI template and resampled to 3 × 3 × 3 mm3 voxels.
43-1	4608-4612	Then	_
43-2	4613-4614	,	_
43-3	4615-4618	the	_
43-4	4619-4629	functional	_
43-5	4630-4635	scans	_
43-6	4636-4640	were	_
43-7	4641-4651	normalized	_
43-8	4652-4654	to	_
43-9	4655-4658	the	_
43-10	4659-4667	Montreal	_
43-11	4668-4680	Neurological	_
43-12	4681-4690	Institute	_
43-13	4691-4692	(	_
43-14	4693-4696	MNI	_
43-15	4697-4698	)	_
43-16	4699-4702	EPI	_
43-17	4703-4711	template	_
43-18	4712-4715	and	_
43-19	4716-4725	resampled	_
43-20	4726-4728	to	_
43-21	4729-4730	3	_
43-22	4731-4732	×	_
43-23	4733-4734	3	_
43-24	4735-4736	×	_
43-25	4737-4738	3	_
43-26	4739-4742	mm3	_
43-27	4743-4749	voxels	_
43-28	4750-4751	.	_

Text=The general processing procedures of spatial smoothing (Gaussian kernel of a full width at half maximum (FWHM) of 6 mm) was not included for the FCS analysis but was included for the FC analysis.
44-1	4752-4755	The	_
44-2	4756-4763	general	_
44-3	4764-4774	processing	_
44-4	4775-4785	procedures	_
44-5	4786-4788	of	_
44-6	4789-4796	spatial	_
44-7	4797-4806	smoothing	_
44-8	4807-4808	(	_
44-9	4809-4817	Gaussian	_
44-10	4818-4824	kernel	_
44-11	4825-4827	of	_
44-12	4828-4829	a	_
44-13	4830-4834	full	_
44-14	4835-4840	width	_
44-15	4841-4843	at	_
44-16	4844-4848	half	_
44-17	4849-4856	maximum	_
44-18	4857-4858	(	_
44-19	4859-4863	FWHM	_
44-20	4864-4865	)	_
44-21	4866-4868	of	_
44-22	4869-4870	6	_
44-23	4871-4873	mm	_
44-24	4874-4875	)	_
44-25	4876-4879	was	_
44-26	4880-4883	not	_
44-27	4884-4892	included	_
44-28	4893-4896	for	_
44-29	4897-4900	the	_
44-30	4901-4904	FCS	_
44-31	4905-4913	analysis	_
44-32	4914-4917	but	_
44-33	4918-4921	was	_
44-34	4922-4930	included	_
44-35	4931-4934	for	_
44-36	4935-4938	the	_
44-37	4939-4941	FC	_
44-38	4942-4950	analysis	_
44-39	4951-4952	.	_

Text=Then, nuisance signals were then removed from the data through linear regression (white matter (WM), cerebrospinal fluid (CSF), and six motion parameters), except the global signal due to recent excellent studies.
45-1	4953-4957	Then	_
45-2	4958-4959	,	_
45-3	4960-4968	nuisance	_
45-4	4969-4976	signals	_
45-5	4977-4981	were	_
45-6	4982-4986	then	_
45-7	4987-4994	removed	_
45-8	4995-4999	from	_
45-9	5000-5003	the	_
45-10	5004-5008	data	_
45-11	5009-5016	through	_
45-12	5017-5023	linear	_
45-13	5024-5034	regression	_
45-14	5035-5036	(	_
45-15	5037-5042	white	_
45-16	5043-5049	matter	_
45-17	5050-5051	(	_
45-18	5052-5054	WM	_
45-19	5055-5056	)	_
45-20	5057-5058	,	_
45-21	5059-5072	cerebrospinal	_
45-22	5073-5078	fluid	_
45-23	5079-5080	(	_
45-24	5081-5084	CSF	_
45-25	5085-5086	)	_
45-26	5087-5088	,	_
45-27	5089-5092	and	_
45-28	5093-5096	six	_
45-29	5097-5103	motion	_
45-30	5104-5114	parameters	_
45-31	5115-5116	)	_
45-32	5117-5118	,	_
45-33	5119-5125	except	_
45-34	5126-5129	the	_
45-35	5130-5136	global	_
45-36	5137-5143	signal	_
45-37	5144-5147	due	_
45-38	5148-5150	to	_
45-39	5151-5157	recent	_
45-40	5158-5167	excellent	_
45-41	5168-5175	studies	_
45-42	5176-5177	.	_

Text=Finally, fMRI data were temporally filtered in band-pass 0.01–0.08 Hz.
46-1	5178-5185	Finally	_
46-2	5186-5187	,	_
46-3	5188-5192	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
46-4	5193-5197	data	_
46-5	5198-5202	were	_
46-6	5203-5213	temporally	_
46-7	5214-5222	filtered	_
46-8	5223-5225	in	_
46-9	5226-5235	band-pass	_
46-10	5236-5245	0.01–0.08	_
46-11	5246-5248	Hz	_
46-12	5249-5250	.	_

Text=Recent studies demonstrated that head motion had a substantial impact on FC.
47-1	5251-5257	Recent	_
47-2	5258-5265	studies	_
47-3	5266-5278	demonstrated	_
47-4	5279-5283	that	_
47-5	5284-5288	head	_
47-6	5289-5295	motion	_
47-7	5296-5299	had	_
47-8	5300-5301	a	_
47-9	5302-5313	substantial	_
47-10	5314-5320	impact	_
47-11	5321-5323	on	_
47-12	5324-5326	FC	_
47-13	5327-5328	.	_

Text=Thus, any subjects who had a maximum translation in any of the cardinal directions larger than 2.0 mm or a maximum rotation larger than 2.0 degrees were excluded.
48-1	5329-5333	Thus	_
48-2	5334-5335	,	_
48-3	5336-5339	any	_
48-4	5340-5348	subjects	_
48-5	5349-5352	who	_
48-6	5353-5356	had	_
48-7	5357-5358	a	_
48-8	5359-5366	maximum	_
48-9	5367-5378	translation	_
48-10	5379-5381	in	_
48-11	5382-5385	any	_
48-12	5386-5388	of	_
48-13	5389-5392	the	_
48-14	5393-5401	cardinal	_
48-15	5402-5412	directions	_
48-16	5413-5419	larger	_
48-17	5420-5424	than	_
48-18	5425-5428	2.0	_
48-19	5429-5431	mm	_
48-20	5432-5434	or	_
48-21	5435-5436	a	_
48-22	5437-5444	maximum	_
48-23	5445-5453	rotation	_
48-24	5454-5460	larger	_
48-25	5461-5465	than	_
48-26	5466-5469	2.0	_
48-27	5470-5477	degrees	_
48-28	5478-5482	were	_
48-29	5483-5491	excluded	_
48-30	5492-5493	.	_

Text=Besides, we also assessed framewise displacement (FD) in three groups as suggested by Power et al.
49-1	5494-5501	Besides	_
49-2	5502-5503	,	_
49-3	5504-5506	we	_
49-4	5507-5511	also	_
49-5	5512-5520	assessed	_
49-6	5521-5530	framewise	_
49-7	5531-5543	displacement	_
49-8	5544-5545	(	_
49-9	5546-5548	FD	_
49-10	5549-5550	)	_
49-11	5551-5553	in	_
49-12	5554-5559	three	_
49-13	5560-5566	groups	_
49-14	5567-5569	as	_
49-15	5570-5579	suggested	_
49-16	5580-5582	by	_
49-17	5583-5588	Power	_
49-18	5589-5591	et	_
49-19	5592-5594	al	_
49-20	5595-5596	.	_

Text=using the following formula: where M is the length of the time courses (M = 250 in this study); x i, y i, and z i are translations/rotations at the ith time point in the x, y, and z directions, respectively; Δt represents the framewise displacement translation; and Δd represents the framewise displacement rotation.
50-1	5597-5602	using	_
50-2	5603-5606	the	_
50-3	5607-5616	following	_
50-4	5617-5624	formula	_
50-5	5625-5626	:	_
50-6	5627-5632	where	_
50-7	5633-5634	M	_
50-8	5635-5637	is	_
50-9	5638-5641	the	_
50-10	5642-5648	length	_
50-11	5649-5651	of	_
50-12	5652-5655	the	_
50-13	5656-5660	time	_
50-14	5661-5668	courses	_
50-15	5669-5670	(	_
50-16	5671-5672	M	_
50-17	5673-5674	=	_
50-18	5675-5678	250	_
50-19	5679-5681	in	_
50-20	5682-5686	this	_
50-21	5687-5692	study	_
50-22	5693-5694	)	_
50-23	5695-5696	;	_
50-24	5697-5698	x	_
50-25	5699-5700	i	_
50-26	5701-5702	,	_
50-27	5703-5704	y	_
50-28	5705-5706	i	_
50-29	5707-5708	,	_
50-30	5709-5712	and	_
50-31	5713-5714	z	_
50-32	5715-5716	i	_
50-33	5717-5720	are	_
50-34	5721-5743	translations/rotations	_
50-35	5744-5746	at	_
50-36	5747-5750	the	_
50-37	5751-5754	ith	_
50-38	5755-5759	time	_
50-39	5760-5765	point	_
50-40	5766-5768	in	_
50-41	5769-5772	the	_
50-42	5773-5774	x	_
50-43	5775-5776	,	_
50-44	5777-5778	y	_
50-45	5779-5780	,	_
50-46	5781-5784	and	_
50-47	5785-5786	z	_
50-48	5787-5797	directions	_
50-49	5798-5799	,	_
50-50	5800-5812	respectively	_
50-51	5813-5814	;	_
50-52	5815-5817	Δt	_
50-53	5818-5828	represents	_
50-54	5829-5832	the	_
50-55	5833-5842	framewise	_
50-56	5843-5855	displacement	_
50-57	5856-5867	translation	_
50-58	5868-5869	;	_
50-59	5870-5873	and	_
50-60	5874-5876	Δd	_
50-61	5877-5887	represents	_
50-62	5888-5891	the	_
50-63	5892-5901	framewise	_
50-64	5902-5914	displacement	_
50-65	5915-5923	rotation	_
50-66	5924-5925	.	_

Text=Δd xi = x i − x i−1 and similar for d yiandd zi.
51-1	5926-5928	Δd	_
51-2	5929-5931	xi	_
51-3	5932-5933	=	_
51-4	5934-5935	x	_
51-5	5936-5937	i	_
51-6	5938-5939	−	_
51-7	5940-5941	x	_
51-8	5942-5945	i−1	_
51-9	5946-5949	and	_
51-10	5950-5957	similar	_
51-11	5958-5961	for	_
51-12	5962-5963	d	_
51-13	5964-5970	yiandd	_
51-14	5971-5973	zi	_
51-15	5974-5975	.	_

Text=Structural images were processed using SPM8 toolbox.
52-1	5976-5986	Structural	_
52-2	5987-5993	images	_
52-3	5994-5998	were	_
52-4	5999-6008	processed	_
52-5	6009-6014	using	_
52-6	6015-6019	SPM8	_
52-7	6020-6027	toolbox	_
52-8	6028-6029	.	_

Text=Spatial normalization to MNI-space was performed using a diffeomorphic anatomical registration through exponentiated lie algebra and segmented into gray matter (GM), WM, and CSF.
53-1	6030-6037	Spatial	_
53-2	6038-6051	normalization	_
53-3	6052-6054	to	_
53-4	6055-6064	MNI-space	_
53-5	6065-6068	was	_
53-6	6069-6078	performed	_
53-7	6079-6084	using	_
53-8	6085-6086	a	_
53-9	6087-6100	diffeomorphic	_
53-10	6101-6111	anatomical	_
53-11	6112-6124	registration	_
53-12	6125-6132	through	_
53-13	6133-6146	exponentiated	_
53-14	6147-6150	lie	_
53-15	6151-6158	algebra	_
53-16	6159-6162	and	_
53-17	6163-6172	segmented	_
53-18	6173-6177	into	_
53-19	6178-6182	gray	_
53-20	6183-6189	matter	_
53-21	6190-6191	(	_
53-22	6192-6194	GM	_
53-23	6195-6196	)	_
53-24	6197-6198	,	_
53-25	6199-6201	WM	_
53-26	6202-6203	,	_
53-27	6204-6207	and	_
53-28	6208-6211	CSF	_
53-29	6212-6213	.	_

Text=The segmented GM and WM were modulated using nonlinear deformation.
54-1	6214-6217	The	_
54-2	6218-6227	segmented	_
54-3	6228-6230	GM	_
54-4	6231-6234	and	_
54-5	6235-6237	WM	_
54-6	6238-6242	were	_
54-7	6243-6252	modulated	_
54-8	6253-6258	using	_
54-9	6259-6268	nonlinear	_
54-10	6269-6280	deformation	_
54-11	6281-6282	.	_

Text=Total Intracranial Volume (TIV) and GM volume and were calculated.
55-1	6283-6288	Total	_
55-2	6289-6301	Intracranial	_
55-3	6302-6308	Volume	_
55-4	6309-6310	(	_
55-5	6311-6314	TIV	_
55-6	6315-6316	)	_
55-7	6317-6320	and	_
55-8	6321-6323	GM	_
55-9	6324-6330	volume	_
55-10	6331-6334	and	_
55-11	6335-6339	were	_
55-12	6340-6350	calculated	_
55-13	6351-6352	.	_

Text=Then, the normalization analysis was performed: the GM volume was divided by the TIV score.
56-1	6353-6357	Then	_
56-2	6358-6359	,	_
56-3	6360-6363	the	_
56-4	6364-6377	normalization	_
56-5	6378-6386	analysis	_
56-6	6387-6390	was	_
56-7	6391-6400	performed	_
56-8	6401-6402	:	_
56-9	6403-6406	the	_
56-10	6407-6409	GM	_
56-11	6410-6416	volume	_
56-12	6417-6420	was	_
56-13	6421-6428	divided	_
56-14	6429-6431	by	_
56-15	6432-6435	the	_
56-16	6436-6439	TIV	_
56-17	6440-6445	score	_
56-18	6446-6447	.	_

Text=The schizophrenic patients' and HC's normalized GM at baseline were entered as a global variable to correct for the global GM volume of different subjects in the statistical analysis.
57-1	6448-6451	The	_
57-2	6452-6465	schizophrenic	_
57-3	6466-6474	patients	_
57-4	6475-6476	'	_
57-5	6477-6480	and	_
57-6	6481-6483	HC	_
57-7	6484-6486	's	_
57-8	6487-6497	normalized	_
57-9	6498-6500	GM	_
57-10	6501-6503	at	_
57-11	6504-6512	baseline	_
57-12	6513-6517	were	_
57-13	6518-6525	entered	_
57-14	6526-6528	as	_
57-15	6529-6530	a	_
57-16	6531-6537	global	_
57-17	6538-6546	variable	_
57-18	6547-6549	to	_
57-19	6550-6557	correct	_
57-20	6558-6561	for	_
57-21	6562-6565	the	_
57-22	6566-6572	global	_
57-23	6573-6575	GM	_
57-24	6576-6582	volume	_
57-25	6583-6585	of	_
57-26	6586-6595	different	_
57-27	6596-6604	subjects	_
57-28	6605-6607	in	_
57-29	6608-6611	the	_
57-30	6612-6623	statistical	_
57-31	6624-6632	analysis	_
57-32	6633-6634	.	_

Text=2.6.
58-1	6635-6638	2.6	_
58-2	6639-6640	.	_

Text=Functional Connectivity Strength Analysis Whole-brain FC analysis was performed as follows.
59-1	6641-6651	Functional	_
59-2	6652-6664	Connectivity	_
59-3	6665-6673	Strength	_
59-4	6674-6682	Analysis	_
59-5	6683-6694	Whole-brain	_
59-6	6695-6697	FC	_
59-7	6698-6706	analysis	_
59-8	6707-6710	was	_
59-9	6711-6720	performed	_
59-10	6721-6723	as	_
59-11	6724-6731	follows	_
59-12	6732-6733	.	_

Text=First, to exclude artefactual correlations from non-gray matter, the GM mask was generated by thresholding (cutoff = 0.2) the average of GM probability map involving all subjects.
60-1	6734-6739	First	_
60-2	6740-6741	,	_
60-3	6742-6744	to	_
60-4	6745-6752	exclude	_
60-5	6753-6764	artefactual	_
60-6	6765-6777	correlations	_
60-7	6778-6782	from	_
60-8	6783-6791	non-gray	_
60-9	6792-6798	matter	_
60-10	6799-6800	,	_
60-11	6801-6804	the	_
60-12	6805-6807	GM	_
60-13	6808-6812	mask	_
60-14	6813-6816	was	_
60-15	6817-6826	generated	_
60-16	6827-6829	by	_
60-17	6830-6842	thresholding	_
60-18	6843-6844	(	_
60-19	6845-6851	cutoff	_
60-20	6852-6853	=	_
60-21	6854-6857	0.2	_
60-22	6858-6859	)	_
60-23	6860-6863	the	_
60-24	6864-6871	average	_
60-25	6872-6874	of	_
60-26	6875-6877	GM	_
60-27	6878-6889	probability	_
60-28	6890-6893	map	_
60-29	6894-6903	involving	_
60-30	6904-6907	all	_
60-31	6908-6916	subjects	_
60-32	6917-6918	.	_

Text=The time series from each voxel within the GM mask was extracted, and Pearson's correlations between any pair of voxels were calculated for each subject.
61-1	6919-6922	The	_
61-2	6923-6927	time	_
61-3	6928-6934	series	_
61-4	6935-6939	from	_
61-5	6940-6944	each	_
61-6	6945-6950	voxel	_
61-7	6951-6957	within	_
61-8	6958-6961	the	_
61-9	6962-6964	GM	_
61-10	6965-6969	mask	_
61-11	6970-6973	was	_
61-12	6974-6983	extracted	_
61-13	6984-6985	,	_
61-14	6986-6989	and	_
61-15	6990-6997	Pearson	_
61-16	6998-7000	's	_
61-17	7001-7013	correlations	_
61-18	7014-7021	between	_
61-19	7022-7025	any	_
61-20	7026-7030	pair	_
61-21	7031-7033	of	_
61-22	7034-7040	voxels	_
61-23	7041-7045	were	_
61-24	7046-7056	calculated	_
61-25	7057-7060	for	_
61-26	7061-7065	each	_
61-27	7066-7073	subject	_
61-28	7074-7075	.	_

Text=To improve normality, we then transformed individual correlation matrices to a z-score matrix using a Fisher r-to-z transformation.
62-1	7076-7078	To	_
62-2	7079-7086	improve	_
62-3	7087-7096	normality	_
62-4	7097-7098	,	_
62-5	7099-7101	we	_
62-6	7102-7106	then	_
62-7	7107-7118	transformed	_
62-8	7119-7129	individual	_
62-9	7130-7141	correlation	_
62-10	7142-7150	matrices	_
62-11	7151-7153	to	_
62-12	7154-7155	a	_
62-13	7156-7163	z-score	_
62-14	7164-7170	matrix	_
62-15	7171-7176	using	_
62-16	7177-7178	a	_
62-17	7179-7185	Fisher	_
62-18	7186-7192	r-to-z	_
62-19	7193-7207	transformation	_
62-20	7208-7209	.	_

Text=Then, for a given voxel (node), nodal FCS was computed as the sum of weights of its connections with other voxels.
63-1	7210-7214	Then	_
63-2	7215-7216	,	_
63-3	7217-7220	for	_
63-4	7221-7222	a	_
63-5	7223-7228	given	_
63-6	7229-7234	voxel	_
63-7	7235-7236	(	_
63-8	7237-7241	node	_
63-9	7242-7243	)	_
63-10	7244-7245	,	_
63-11	7246-7251	nodal	_
63-12	7252-7255	FCS	_
63-13	7256-7259	was	_
63-14	7260-7268	computed	_
63-15	7269-7271	as	_
63-16	7272-7275	the	_
63-17	7276-7279	sum	_
63-18	7280-7282	of	_
63-19	7283-7290	weights	_
63-20	7291-7293	of	_
63-21	7294-7297	its	_
63-22	7298-7309	connections	_
63-23	7310-7314	with	_
63-24	7315-7320	other	_
63-25	7321-7327	voxels	_
63-26	7328-7329	.	_

Text=We conservatively restricted our analysis to positive correlations above the threshold of r = 0.2, which was chosen to eliminate the voxels with weak correlations attributable to signal noise.
64-1	7330-7332	We	_
64-2	7333-7347	conservatively	_
64-3	7348-7358	restricted	_
64-4	7359-7362	our	_
64-5	7363-7371	analysis	_
64-6	7372-7374	to	_
64-7	7375-7383	positive	_
64-8	7384-7396	correlations	_
64-9	7397-7402	above	_
64-10	7403-7406	the	_
64-11	7407-7416	threshold	_
64-12	7417-7419	of	_
64-13	7420-7421	r	_
64-14	7422-7423	=	_
64-15	7424-7427	0.2	_
64-16	7428-7429	,	_
64-17	7430-7435	which	_
64-18	7436-7439	was	_
64-19	7440-7446	chosen	_
64-20	7447-7449	to	_
64-21	7450-7459	eliminate	_
64-22	7460-7463	the	_
64-23	7464-7470	voxels	_
64-24	7471-7475	with	_
64-25	7476-7480	weak	_
64-26	7481-7493	correlations	_
64-27	7494-7506	attributable	_
64-28	7507-7509	to	_
64-29	7510-7516	signal	_
64-30	7517-7522	noise	_
64-31	7523-7524	.	_

Text=Before group-level statistical analysis, an individual voxel-wise FCS map was standardized to z-scores and further spatially smoothed (FWHM = 6 mm).
65-1	7525-7531	Before	_
65-2	7532-7543	group-level	_
65-3	7544-7555	statistical	_
65-4	7556-7564	analysis	_
65-5	7565-7566	,	_
65-6	7567-7569	an	_
65-7	7570-7580	individual	_
65-8	7581-7591	voxel-wise	_
65-9	7592-7595	FCS	_
65-10	7596-7599	map	_
65-11	7600-7603	was	_
65-12	7604-7616	standardized	_
65-13	7617-7619	to	_
65-14	7620-7628	z-scores	_
65-15	7629-7632	and	_
65-16	7633-7640	further	_
65-17	7641-7650	spatially	_
65-18	7651-7659	smoothed	_
65-19	7660-7661	(	_
65-20	7662-7666	FWHM	_
65-21	7667-7668	=	_
65-22	7669-7670	6	_
65-23	7671-7673	mm	_
65-24	7674-7675	)	_
65-25	7676-7677	.	_

Text=2.7.
66-1	7678-7681	2.7	_
66-2	7682-7683	.	_

Text=Functional Connectivity Analysis We examined FC by taking the brain region that had showed different FCS (pursuant to the FCS statistical test) as the seed.
67-1	7684-7694	Functional	_
67-2	7695-7707	Connectivity	_
67-3	7708-7716	Analysis	_
67-4	7717-7719	We	_
67-5	7720-7728	examined	_
67-6	7729-7731	FC	_
67-7	7732-7734	by	_
67-8	7735-7741	taking	_
67-9	7742-7745	the	_
67-10	7746-7751	brain	_
67-11	7752-7758	region	_
67-12	7759-7763	that	_
67-13	7764-7767	had	_
67-14	7768-7774	showed	_
67-15	7775-7784	different	_
67-16	7785-7788	FCS	_
67-17	7789-7790	(	_
67-18	7791-7799	pursuant	_
67-19	7800-7802	to	_
67-20	7803-7806	the	_
67-21	7807-7810	FCS	_
67-22	7811-7822	statistical	_
67-23	7823-7827	test	_
67-24	7828-7829	)	_
67-25	7830-7832	as	_
67-26	7833-7836	the	_
67-27	7837-7841	seed	_
67-28	7842-7843	.	_

Text=FC analysis was performed between the seed and all voxels in the brain.
68-1	7844-7846	FC	_
68-2	7847-7855	analysis	_
68-3	7856-7859	was	_
68-4	7860-7869	performed	_
68-5	7870-7877	between	_
68-6	7878-7881	the	_
68-7	7882-7886	seed	_
68-8	7887-7890	and	_
68-9	7891-7894	all	_
68-10	7895-7901	voxels	_
68-11	7902-7904	in	_
68-12	7905-7908	the	_
68-13	7909-7914	brain	_
68-14	7915-7916	.	_

Text=To improve normality, we then transformed individual correlation matrices to a z-score matrix using a Fisher r-to-z transformation.
69-1	7917-7919	To	_
69-2	7920-7927	improve	_
69-3	7928-7937	normality	_
69-4	7938-7939	,	_
69-5	7940-7942	we	_
69-6	7943-7947	then	_
69-7	7948-7959	transformed	_
69-8	7960-7970	individual	_
69-9	7971-7982	correlation	_
69-10	7983-7991	matrices	_
69-11	7992-7994	to	_
69-12	7995-7996	a	_
69-13	7997-8004	z-score	_
69-14	8005-8011	matrix	_
69-15	8012-8017	using	_
69-16	8018-8019	a	_
69-17	8020-8026	Fisher	_
69-18	8027-8033	r-to-z	_
69-19	8034-8048	transformation	_
69-20	8049-8050	.	_

Text=In this manner, FC maps of these seeds were produced for each subject.
70-1	8051-8053	In	_
70-2	8054-8058	this	_
70-3	8059-8065	manner	_
70-4	8066-8067	,	_
70-5	8068-8070	FC	_
70-6	8071-8075	maps	_
70-7	8076-8078	of	_
70-8	8079-8084	these	_
70-9	8085-8090	seeds	_
70-10	8091-8095	were	_
70-11	8096-8104	produced	_
70-12	8105-8108	for	_
70-13	8109-8113	each	_
70-14	8114-8121	subject	_
70-15	8122-8123	.	_

Text=2.8.
71-1	8124-8127	2.8	_
71-2	8128-8129	.	_

Text=Statistical Analysis 2.8.1.
72-1	8130-8141	Statistical	_
72-2	8142-8150	Analysis	_
72-3	8151-8156	2.8.1	_
72-4	8157-8158	.	_

Text=Participant Fundamental Information Statistics Age, years of education, and FD among the three groups were compared using one-way ANOVA.
73-1	8159-8170	Participant	_
73-2	8171-8182	Fundamental	_
73-3	8183-8194	Information	_
73-4	8195-8205	Statistics	_
73-5	8206-8209	Age	_
73-6	8210-8211	,	_
73-7	8212-8217	years	_
73-8	8218-8220	of	_
73-9	8221-8230	education	_
73-10	8231-8232	,	_
73-11	8233-8236	and	_
73-12	8237-8239	FD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
73-13	8240-8245	among	_
73-14	8246-8249	the	_
73-15	8250-8255	three	_
73-16	8256-8262	groups	_
73-17	8263-8267	were	_
73-18	8268-8276	compared	_
73-19	8277-8282	using	_
73-20	8283-8290	one-way	_
73-21	8291-8296	ANOVA	_
73-22	8297-8298	.	_

Text=Chi-square test was used to compare gender distributions.
74-1	8299-8309	Chi-square	_
74-2	8310-8314	test	_
74-3	8315-8318	was	_
74-4	8319-8323	used	_
74-5	8324-8326	to	_
74-6	8327-8334	compare	_
74-7	8335-8341	gender	_
74-8	8342-8355	distributions	_
74-9	8356-8357	.	_

Text=A two-sample t-test was used to compare the psychiatric symptoms (illness duration, medication dosage in chlorpromazine (CPZ) equivalents (mg), and PANSS scores) between two groups of patients at baseline.
75-1	8358-8359	A	_
75-2	8360-8370	two-sample	_
75-3	8371-8377	t-test	_
75-4	8378-8381	was	_
75-5	8382-8386	used	_
75-6	8387-8389	to	_
75-7	8390-8397	compare	_
75-8	8398-8401	the	_
75-9	8402-8413	psychiatric	_
75-10	8414-8422	symptoms	_
75-11	8423-8424	(	_
75-12	8425-8432	illness	_
75-13	8433-8441	duration	_
75-14	8442-8443	,	_
75-15	8444-8454	medication	_
75-16	8455-8461	dosage	_
75-17	8462-8464	in	_
75-18	8465-8479	chlorpromazine	_
75-19	8480-8481	(	_
75-20	8482-8485	CPZ	_
75-21	8486-8487	)	_
75-22	8488-8499	equivalents	_
75-23	8500-8501	(	_
75-24	8502-8504	mg	_
75-25	8505-8506	)	_
75-26	8507-8508	,	_
75-27	8509-8512	and	_
75-28	8513-8518	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
75-29	8519-8525	scores	_
75-30	8526-8527	)	_
75-31	8528-8535	between	_
75-32	8536-8539	two	_
75-33	8540-8546	groups	_
75-34	8547-8549	of	_
75-35	8550-8558	patients	_
75-36	8559-8561	at	_
75-37	8562-8570	baseline	_
75-38	8571-8572	.	_

Text=Repeated measure ANOVA were performed to determine the music intervention∗time interaction, main effects of music intervention and time on neuropsychological measurements, and PANSS scores.
76-1	8573-8581	Repeated	_
76-2	8582-8589	measure	_
76-3	8590-8595	ANOVA	_
76-4	8596-8600	were	_
76-5	8601-8610	performed	_
76-6	8611-8613	to	_
76-7	8614-8623	determine	_
76-8	8624-8627	the	_
76-9	8628-8633	music	_
76-10	8634-8651	intervention∗time	_
76-11	8652-8663	interaction	_
76-12	8664-8665	,	_
76-13	8666-8670	main	_
76-14	8671-8678	effects	_
76-15	8679-8681	of	_
76-16	8682-8687	music	_
76-17	8688-8700	intervention	_
76-18	8701-8704	and	_
76-19	8705-8709	time	_
76-20	8710-8712	on	_
76-21	8713-8731	neuropsychological	_
76-22	8732-8744	measurements	_
76-23	8745-8746	,	_
76-24	8747-8750	and	_
76-25	8751-8756	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
76-26	8757-8763	scores	_
76-27	8764-8765	.	_

Text=2.8.2.
77-1	8766-8771	2.8.2	_
77-2	8772-8773	.	_

Text=Baseline Brain Connectivity Analyses between Patients and HC Firstly, we established baseline abnormalities between HCs and schizophrenic patients through two-sample t-test in FCS and seed-based FC, respectively, with age, gender, years of education, and GM as covariates.
78-1	8774-8782	Baseline	_
78-2	8783-8788	Brain	_
78-3	8789-8801	Connectivity	_
78-4	8802-8810	Analyses	_
78-5	8811-8818	between	_
78-6	8819-8827	Patients	_
78-7	8828-8831	and	_
78-8	8832-8834	HC	_
78-9	8835-8842	Firstly	_
78-10	8843-8844	,	_
78-11	8845-8847	we	_
78-12	8848-8859	established	_
78-13	8860-8868	baseline	_
78-14	8869-8882	abnormalities	_
78-15	8883-8890	between	_
78-16	8891-8894	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
78-17	8895-8898	and	_
78-18	8899-8912	schizophrenic	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
78-19	8913-8921	patients	_
78-20	8922-8929	through	_
78-21	8930-8940	two-sample	_
78-22	8941-8947	t-test	_
78-23	8948-8950	in	_
78-24	8951-8954	FCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
78-25	8955-8958	and	_
78-26	8959-8969	seed-based	_
78-27	8970-8972	FC	_
78-28	8973-8974	,	_
78-29	8975-8987	respectively	_
78-30	8988-8989	,	_
78-31	8990-8994	with	_
78-32	8995-8998	age	_
78-33	8999-9000	,	_
78-34	9001-9007	gender	_
78-35	9008-9009	,	_
78-36	9010-9015	years	_
78-37	9016-9018	of	_
78-38	9019-9028	education	_
78-39	9029-9030	,	_
78-40	9031-9034	and	_
78-41	9035-9037	GM	_
78-42	9038-9040	as	_
78-43	9041-9051	covariates	_
78-44	9052-9053	.	_

Text=The comparison, for the FCS statistical test, was constrained within the GM mask.
79-1	9054-9057	The	_
79-2	9058-9068	comparison	_
79-3	9069-9070	,	_
79-4	9071-9074	for	_
79-5	9075-9078	the	_
79-6	9079-9082	FCS	_
79-7	9083-9094	statistical	_
79-8	9095-9099	test	_
79-9	9100-9101	,	_
79-10	9102-9105	was	_
79-11	9106-9117	constrained	_
79-12	9118-9124	within	_
79-13	9125-9128	the	_
79-14	9129-9131	GM	_
79-15	9132-9136	mask	_
79-16	9137-9138	.	_

Text=The seed-based FC statistical test was performed within the mask that resulted from the union set of the one-sample t-test of the two groups (p <0.005 with cluster-level false discovery rate corrected, p <0.05).
80-1	9139-9142	The	_
80-2	9143-9153	seed-based	_
80-3	9154-9156	FC	_
80-4	9157-9168	statistical	_
80-5	9169-9173	test	_
80-6	9174-9177	was	_
80-7	9178-9187	performed	_
80-8	9188-9194	within	_
80-9	9195-9198	the	_
80-10	9199-9203	mask	_
80-11	9204-9208	that	_
80-12	9209-9217	resulted	_
80-13	9218-9222	from	_
80-14	9223-9226	the	_
80-15	9227-9232	union	_
80-16	9233-9236	set	_
80-17	9237-9239	of	_
80-18	9240-9243	the	_
80-19	9244-9254	one-sample	_
80-20	9255-9261	t-test	_
80-21	9262-9264	of	_
80-22	9265-9268	the	_
80-23	9269-9272	two	_
80-24	9273-9279	groups	_
80-25	9280-9281	(	_
80-26	9282-9283	p	_
80-27	9284-9285	<	_
80-28	9286-9291	0.005	_
80-29	9292-9296	with	_
80-30	9297-9310	cluster-level	_
80-31	9311-9316	false	_
80-32	9317-9326	discovery	_
80-33	9327-9331	rate	_
80-34	9332-9341	corrected	_
80-35	9342-9343	,	_
80-36	9344-9345	p	_
80-37	9346-9347	<	_
80-38	9348-9352	0.05	_
80-39	9353-9354	)	_
80-40	9355-9356	.	_

Text=Due to the quantity of patients being greater than the amount of HC, the HC and the same number of patients who were randomly selected from the whole sample of patients were entered into the statistical comparisons.
81-1	9357-9360	Due	_
81-2	9361-9363	to	_
81-3	9364-9367	the	_
81-4	9368-9376	quantity	_
81-5	9377-9379	of	_
81-6	9380-9388	patients	_
81-7	9389-9394	being	_
81-8	9395-9402	greater	_
81-9	9403-9407	than	_
81-10	9408-9411	the	_
81-11	9412-9418	amount	_
81-12	9419-9421	of	_
81-13	9422-9424	HC	_
81-14	9425-9426	,	_
81-15	9427-9430	the	_
81-16	9431-9433	HC	_
81-17	9434-9437	and	_
81-18	9438-9441	the	_
81-19	9442-9446	same	_
81-20	9447-9453	number	_
81-21	9454-9456	of	_
81-22	9457-9465	patients	_
81-23	9466-9469	who	_
81-24	9470-9474	were	_
81-25	9475-9483	randomly	_
81-26	9484-9492	selected	_
81-27	9493-9497	from	_
81-28	9498-9501	the	_
81-29	9502-9507	whole	_
81-30	9508-9514	sample	_
81-31	9515-9517	of	_
81-32	9518-9526	patients	_
81-33	9527-9531	were	_
81-34	9532-9539	entered	_
81-35	9540-9544	into	_
81-36	9545-9548	the	_
81-37	9549-9560	statistical	_
81-38	9561-9572	comparisons	_
81-39	9573-9574	.	_

Text=These steps were repeatedly performed 200 times.
82-1	9575-9580	These	_
82-2	9581-9586	steps	_
82-3	9587-9591	were	_
82-4	9592-9602	repeatedly	_
82-5	9603-9612	performed	_
82-6	9613-9616	200	_
82-7	9617-9622	times	_
82-8	9623-9624	.	_

Text=A total of 200 comparison results were obtained.
83-1	9625-9626	A	_
83-2	9627-9632	total	_
83-3	9633-9635	of	_
83-4	9636-9639	200	_
83-5	9640-9650	comparison	_
83-6	9651-9658	results	_
83-7	9659-9663	were	_
83-8	9664-9672	obtained	_
83-9	9673-9674	.	_

Text=Then, we calculated the probability map where the voxels exhibited significant differences (p <0.005 with cluster-level false discovery rate corrected, p <0.05) across the 200 comparisons.
84-1	9675-9679	Then	_
84-2	9680-9681	,	_
84-3	9682-9684	we	_
84-4	9685-9695	calculated	_
84-5	9696-9699	the	_
84-6	9700-9711	probability	_
84-7	9712-9715	map	_
84-8	9716-9721	where	_
84-9	9722-9725	the	_
84-10	9726-9732	voxels	_
84-11	9733-9742	exhibited	_
84-12	9743-9754	significant	_
84-13	9755-9766	differences	_
84-14	9767-9768	(	_
84-15	9769-9770	p	_
84-16	9771-9772	<	_
84-17	9773-9778	0.005	_
84-18	9779-9783	with	_
84-19	9784-9797	cluster-level	_
84-20	9798-9803	false	_
84-21	9804-9813	discovery	_
84-22	9814-9818	rate	_
84-23	9819-9828	corrected	_
84-24	9829-9830	,	_
84-25	9831-9832	p	_
84-26	9833-9834	<	_
84-27	9835-9839	0.05	_
84-28	9840-9841	)	_
84-29	9842-9848	across	_
84-30	9849-9852	the	_
84-31	9853-9856	200	_
84-32	9857-9868	comparisons	_
84-33	9869-9870	.	_

Text=Furthermore, we also established the difference between MTSZ and UMTSZ at baseline through a two-sample t-test in FCS and seed-based FC, respectively, with gender, years of education, GM, and age as covariates.
85-1	9871-9882	Furthermore	_
85-2	9883-9884	,	_
85-3	9885-9887	we	_
85-4	9888-9892	also	_
85-5	9893-9904	established	_
85-6	9905-9908	the	_
85-7	9909-9919	difference	_
85-8	9920-9927	between	_
85-9	9928-9932	MTSZ	_
85-10	9933-9936	and	_
85-11	9937-9942	UMTSZ	_
85-12	9943-9945	at	_
85-13	9946-9954	baseline	_
85-14	9955-9962	through	_
85-15	9963-9964	a	_
85-16	9965-9975	two-sample	_
85-17	9976-9982	t-test	_
85-18	9983-9985	in	_
85-19	9986-9989	FCS	_
85-20	9990-9993	and	_
85-21	9994-10004	seed-based	_
85-22	10005-10007	FC	_
85-23	10008-10009	,	_
85-24	10010-10022	respectively	_
85-25	10023-10024	,	_
85-26	10025-10029	with	_
85-27	10030-10036	gender	_
85-28	10037-10038	,	_
85-29	10039-10044	years	_
85-30	10045-10047	of	_
85-31	10048-10057	education	_
85-32	10058-10059	,	_
85-33	10060-10062	GM	_
85-34	10063-10064	,	_
85-35	10065-10068	and	_
85-36	10069-10072	age	_
85-37	10073-10075	as	_
85-38	10076-10086	covariates	_
85-39	10087-10088	.	_

Text=The significance threshold of the group difference was set to p <0.05.
86-1	10089-10092	The	_
86-2	10093-10105	significance	_
86-3	10106-10115	threshold	_
86-4	10116-10118	of	_
86-5	10119-10122	the	_
86-6	10123-10128	group	_
86-7	10129-10139	difference	_
86-8	10140-10143	was	_
86-9	10144-10147	set	_
86-10	10148-10150	to	_
86-11	10151-10152	p	_
86-12	10153-10154	<	_
86-13	10155-10159	0.05	_
86-14	10160-10161	.	_

Text=2.8.3.
87-1	10162-10167	2.8.3	_
87-2	10168-10169	.	_

Text=Longitudinal Analysis of Functional Connectivity in Patients After tests of normality, homogeneity of variance, and Mauchly's test of sphericity, the repeated-measure ANOVA and post hoc analyses were performed on the schizophrenic subjects from baseline and 1-month follow-up to determine the music intervention∗time interaction, main effects of music intervention, and time on FCS and seed-based FC, respectively.
88-1	10170-10182	Longitudinal	_
88-2	10183-10191	Analysis	_
88-3	10192-10194	of	_
88-4	10195-10205	Functional	_
88-5	10206-10218	Connectivity	_
88-6	10219-10221	in	_
88-7	10222-10230	Patients	_
88-8	10231-10236	After	_
88-9	10237-10242	tests	_
88-10	10243-10245	of	_
88-11	10246-10255	normality	_
88-12	10256-10257	,	_
88-13	10258-10269	homogeneity	_
88-14	10270-10272	of	_
88-15	10273-10281	variance	_
88-16	10282-10283	,	_
88-17	10284-10287	and	_
88-18	10288-10295	Mauchly	_
88-19	10296-10298	's	_
88-20	10299-10303	test	_
88-21	10304-10306	of	_
88-22	10307-10317	sphericity	_
88-23	10318-10319	,	_
88-24	10320-10323	the	_
88-25	10324-10340	repeated-measure	_
88-26	10341-10346	ANOVA	_
88-27	10347-10350	and	_
88-28	10351-10355	post	_
88-29	10356-10359	hoc	_
88-30	10360-10368	analyses	_
88-31	10369-10373	were	_
88-32	10374-10383	performed	_
88-33	10384-10386	on	_
88-34	10387-10390	the	_
88-35	10391-10404	schizophrenic	_
88-36	10405-10413	subjects	_
88-37	10414-10418	from	_
88-38	10419-10427	baseline	_
88-39	10428-10431	and	_
88-40	10432-10439	1-month	_
88-41	10440-10449	follow-up	_
88-42	10450-10452	to	_
88-43	10453-10462	determine	_
88-44	10463-10466	the	_
88-45	10467-10472	music	_
88-46	10473-10490	intervention∗time	_
88-47	10491-10502	interaction	_
88-48	10503-10504	,	_
88-49	10505-10509	main	_
88-50	10510-10517	effects	_
88-51	10518-10520	of	_
88-52	10521-10526	music	_
88-53	10527-10539	intervention	_
88-54	10540-10541	,	_
88-55	10542-10545	and	_
88-56	10546-10550	time	_
88-57	10551-10553	on	_
88-58	10554-10557	FCS	_
88-59	10558-10561	and	_
88-60	10562-10572	seed-based	_
88-61	10573-10575	FC	_
88-62	10576-10577	,	_
88-63	10578-10590	respectively	_
88-64	10591-10592	.	_

Text=The age, gender, illness duration, education characteristics, GM, and the medication dosage were used as covariates.
89-1	10593-10596	The	_
89-2	10597-10600	age	_
89-3	10601-10602	,	_
89-4	10603-10609	gender	_
89-5	10610-10611	,	_
89-6	10612-10619	illness	_
89-7	10620-10628	duration	_
89-8	10629-10630	,	_
89-9	10631-10640	education	_
89-10	10641-10656	characteristics	_
89-11	10657-10658	,	_
89-12	10659-10661	GM	_
89-13	10662-10663	,	_
89-14	10664-10667	and	_
89-15	10668-10671	the	_
89-16	10672-10682	medication	_
89-17	10683-10689	dosage	_
89-18	10690-10694	were	_
89-19	10695-10699	used	_
89-20	10700-10702	as	_
89-21	10703-10713	covariates	_
89-22	10714-10715	.	_

Text=The significance threshold for ANOVA was set to p <0.005 with cluster-level false discovery rate corrected (p <0.05).
90-1	10716-10719	The	_
90-2	10720-10732	significance	_
90-3	10733-10742	threshold	_
90-4	10743-10746	for	_
90-5	10747-10752	ANOVA	_
90-6	10753-10756	was	_
90-7	10757-10760	set	_
90-8	10761-10763	to	_
90-9	10764-10765	p	_
90-10	10766-10767	<	_
90-11	10768-10773	0.005	_
90-12	10774-10778	with	_
90-13	10779-10792	cluster-level	_
90-14	10793-10798	false	_
90-15	10799-10808	discovery	_
90-16	10809-10813	rate	_
90-17	10814-10823	corrected	_
90-18	10824-10825	(	_
90-19	10826-10827	p	_
90-20	10828-10829	<	_
90-21	10830-10834	0.05	_
90-22	10835-10836	)	_
90-23	10837-10838	.	_

Text=For the region with difference resulted from repeated-measure ANOVA, a further two-sample t-test was performed between HC and patients (MTSZ and UMTSZ from 1-month follow-up) to assess the effect of the 1-month music intervention on patients relative to HC.
91-1	10839-10842	For	_
91-2	10843-10846	the	_
91-3	10847-10853	region	_
91-4	10854-10858	with	_
91-5	10859-10869	difference	_
91-6	10870-10878	resulted	_
91-7	10879-10883	from	_
91-8	10884-10900	repeated-measure	_
91-9	10901-10906	ANOVA	_
91-10	10907-10908	,	_
91-11	10909-10910	a	_
91-12	10911-10918	further	_
91-13	10919-10929	two-sample	_
91-14	10930-10936	t-test	_
91-15	10937-10940	was	_
91-16	10941-10950	performed	_
91-17	10951-10958	between	_
91-18	10959-10961	HC	_
91-19	10962-10965	and	_
91-20	10966-10974	patients	_
91-21	10975-10976	(	_
91-22	10977-10981	MTSZ	_
91-23	10982-10985	and	_
91-24	10986-10991	UMTSZ	_
91-25	10992-10996	from	_
91-26	10997-11004	1-month	_
91-27	11005-11014	follow-up	_
91-28	11015-11016	)	_
91-29	11017-11019	to	_
91-30	11020-11026	assess	_
91-31	11027-11030	the	_
91-32	11031-11037	effect	_
91-33	11038-11040	of	_
91-34	11041-11044	the	_
91-35	11045-11052	1-month	_
91-36	11053-11058	music	_
91-37	11059-11071	intervention	_
91-38	11072-11074	on	_
91-39	11075-11083	patients	_
91-40	11084-11092	relative	_
91-41	11093-11095	to	_
91-42	11096-11098	HC	_
91-43	11099-11100	.	_

Text=At last, the data with the 6-month follow-up was used to evaluate the long-term effect of music intervention through the comparison to data from the 1-month follow-up in schizophrenic subjects.
92-1	11101-11103	At	_
92-2	11104-11108	last	_
92-3	11109-11110	,	_
92-4	11111-11114	the	_
92-5	11115-11119	data	_
92-6	11120-11124	with	_
92-7	11125-11128	the	_
92-8	11129-11136	6-month	_
92-9	11137-11146	follow-up	_
92-10	11147-11150	was	_
92-11	11151-11155	used	_
92-12	11156-11158	to	_
92-13	11159-11167	evaluate	_
92-14	11168-11171	the	_
92-15	11172-11181	long-term	_
92-16	11182-11188	effect	_
92-17	11189-11191	of	_
92-18	11192-11197	music	_
92-19	11198-11210	intervention	_
92-20	11211-11218	through	_
92-21	11219-11222	the	_
92-22	11223-11233	comparison	_
92-23	11234-11236	to	_
92-24	11237-11241	data	_
92-25	11242-11246	from	_
92-26	11247-11250	the	_
92-27	11251-11258	1-month	_
92-28	11259-11268	follow-up	_
92-29	11269-11271	in	_
92-30	11272-11285	schizophrenic	_
92-31	11286-11294	subjects	_
92-32	11295-11296	.	_

Text=2.9.
93-1	11297-11300	2.9	_
93-2	11301-11302	.	_

Text=The Relationship between FC and Patients' Variables To investigate the underlying relationship between the changes of functional measurements (i.e., FCS and seed-based FC) and the changes of neuropsychological measurements, as well as PANSS in the MTSZ and UMTSZ groups, we used partial correlation analysis in this study.
94-1	11303-11306	The	_
94-2	11307-11319	Relationship	_
94-3	11320-11327	between	_
94-4	11328-11330	FC	_
94-5	11331-11334	and	_
94-6	11335-11343	Patients	_
94-7	11344-11345	'	_
94-8	11346-11355	Variables	_
94-9	11356-11358	To	_
94-10	11359-11370	investigate	_
94-11	11371-11374	the	_
94-12	11375-11385	underlying	_
94-13	11386-11398	relationship	_
94-14	11399-11406	between	_
94-15	11407-11410	the	_
94-16	11411-11418	changes	_
94-17	11419-11421	of	_
94-18	11422-11432	functional	_
94-19	11433-11445	measurements	_
94-20	11446-11447	(	_
94-21	11448-11452	i.e.	_
94-22	11453-11454	,	_
94-23	11455-11458	FCS	_
94-24	11459-11462	and	_
94-25	11463-11473	seed-based	_
94-26	11474-11476	FC	_
94-27	11477-11478	)	_
94-28	11479-11482	and	_
94-29	11483-11486	the	_
94-30	11487-11494	changes	_
94-31	11495-11497	of	_
94-32	11498-11516	neuropsychological	_
94-33	11517-11529	measurements	_
94-34	11530-11531	,	_
94-35	11532-11534	as	_
94-36	11535-11539	well	_
94-37	11540-11542	as	_
94-38	11543-11548	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
94-39	11549-11551	in	_
94-40	11552-11555	the	_
94-41	11556-11560	MTSZ	_
94-42	11561-11564	and	_
94-43	11565-11570	UMTSZ	_
94-44	11571-11577	groups	_
94-45	11578-11579	,	_
94-46	11580-11582	we	_
94-47	11583-11587	used	_
94-48	11588-11595	partial	_
94-49	11596-11607	correlation	_
94-50	11608-11616	analysis	_
94-51	11617-11619	in	_
94-52	11620-11624	this	_
94-53	11625-11630	study	_
94-54	11631-11632	.	_

Text=We extracted the mean z-score of the region that showed significant difference of FCS and FC.
95-1	11633-11635	We	_
95-2	11636-11645	extracted	_
95-3	11646-11649	the	_
95-4	11650-11654	mean	_
95-5	11655-11662	z-score	_
95-6	11663-11665	of	_
95-7	11666-11669	the	_
95-8	11670-11676	region	_
95-9	11677-11681	that	_
95-10	11682-11688	showed	_
95-11	11689-11700	significant	_
95-12	11701-11711	difference	_
95-13	11712-11714	of	_
95-14	11715-11718	FCS	_
95-15	11719-11722	and	_
95-16	11723-11725	FC	_
95-17	11726-11727	.	_

Text=Then, the partial correlations between the mean changes (1-month later minus baseline) and the percentage change scores (1 − [score at 1-month/score at baseline]) of neuropsychological measurements were performed, as well as the percentage change scores of PANSS, with age, gender, illness duration, education characteristics, GM, and medication dosage as covariates.
96-1	11728-11732	Then	_
96-2	11733-11734	,	_
96-3	11735-11738	the	_
96-4	11739-11746	partial	_
96-5	11747-11759	correlations	_
96-6	11760-11767	between	_
96-7	11768-11771	the	_
96-8	11772-11776	mean	_
96-9	11777-11784	changes	_
96-10	11785-11786	(	_
96-11	11787-11794	1-month	_
96-12	11795-11800	later	_
96-13	11801-11806	minus	_
96-14	11807-11815	baseline	_
96-15	11816-11817	)	_
96-16	11818-11821	and	_
96-17	11822-11825	the	_
96-18	11826-11836	percentage	_
96-19	11837-11843	change	_
96-20	11844-11850	scores	_
96-21	11851-11852	(	_
96-22	11853-11854	1	_
96-23	11855-11856	−	_
96-24	11857-11858	[	_
96-25	11859-11864	score	_
96-26	11865-11867	at	_
96-27	11868-11881	1-month/score	_
96-28	11882-11884	at	_
96-29	11885-11893	baseline	_
96-30	11894-11895	]	_
96-31	11896-11897	)	_
96-32	11898-11900	of	_
96-33	11901-11919	neuropsychological	_
96-34	11920-11932	measurements	_
96-35	11933-11937	were	_
96-36	11938-11947	performed	_
96-37	11948-11949	,	_
96-38	11950-11952	as	_
96-39	11953-11957	well	_
96-40	11958-11960	as	_
96-41	11961-11964	the	_
96-42	11965-11975	percentage	_
96-43	11976-11982	change	_
96-44	11983-11989	scores	_
96-45	11990-11992	of	_
96-46	11993-11998	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
96-47	11999-12000	,	_
96-48	12001-12005	with	_
96-49	12006-12009	age	_
96-50	12010-12011	,	_
96-51	12012-12018	gender	_
96-52	12019-12020	,	_
96-53	12021-12028	illness	_
96-54	12029-12037	duration	_
96-55	12038-12039	,	_
96-56	12040-12049	education	_
96-57	12050-12065	characteristics	_
96-58	12066-12067	,	_
96-59	12068-12070	GM	_
96-60	12071-12072	,	_
96-61	12073-12076	and	_
96-62	12077-12087	medication	_
96-63	12088-12094	dosage	_
96-64	12095-12097	as	_
96-65	12098-12108	covariates	_
96-66	12109-12110	.	_

Text=The partial correlation analysis was also performed between the mean changes (6 months later minus baseline) and the percentage change scores (1 − [score at 6 months/score at baseline]) of neuropsychological and PANSS scores.
97-1	12111-12114	The	_
97-2	12115-12122	partial	_
97-3	12123-12134	correlation	_
97-4	12135-12143	analysis	_
97-5	12144-12147	was	_
97-6	12148-12152	also	_
97-7	12153-12162	performed	_
97-8	12163-12170	between	_
97-9	12171-12174	the	_
97-10	12175-12179	mean	_
97-11	12180-12187	changes	_
97-12	12188-12189	(	_
97-13	12190-12191	6	_
97-14	12192-12198	months	_
97-15	12199-12204	later	_
97-16	12205-12210	minus	_
97-17	12211-12219	baseline	_
97-18	12220-12221	)	_
97-19	12222-12225	and	_
97-20	12226-12229	the	_
97-21	12230-12240	percentage	_
97-22	12241-12247	change	_
97-23	12248-12254	scores	_
97-24	12255-12256	(	_
97-25	12257-12258	1	_
97-26	12259-12260	−	_
97-27	12261-12262	[	_
97-28	12263-12268	score	_
97-29	12269-12271	at	_
97-30	12272-12273	6	_
97-31	12274-12286	months/score	_
97-32	12287-12289	at	_
97-33	12290-12298	baseline	_
97-34	12299-12300	]	_
97-35	12301-12302	)	_
97-36	12303-12305	of	_
97-37	12306-12324	neuropsychological	_
97-38	12325-12328	and	_
97-39	12329-12334	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
97-40	12335-12341	scores	_
97-41	12342-12343	.	_

